Controversies in Urology: Locally Advanced Bladder Cancer - Multidisciplinary Management After Systemic Therapy Response

Co-Chair(s)

• 

  Hammad Ather

  Professor
  Aga Khan University, Pakistan
• 

  Sudhir Rawal

  MEDICAL DIRECTOR & CHIEF OF URO-GENITO ONCOLOGY
  Rajiv Gandhi Cancer Institute & Research Centre, India

Presentations:

• 14:00 - 14:08 CET

  Evolving Standards of Systemic Therapy in Locally Advanced and Metastatic Bladder Cancer Based on Global Access
  

  Speaker: Karima Oualla – Hassan II University Hospital
• 14:08 - 14:16 CET

  Imaging and staging of node-positive and M1a bladder cancer: CT vs PET and response assessment pitfalls
  

  Speaker: Elena Bertelli
• 14:16 CET

  WHAT NEXT AFTER COMPLETE RESPONSE TO SYSTEMIC THERAPY IN N+/M1 DISEASE
• 14:17 - 14:20 CET

  DEBATE: N1/2 Disease After Response to Systemic Therapy - Post-response Local Management in N1/N2 Disease (Introduction)
  

  Speaker: Hammad Ather – Aga Khan University
• 14:20 - 14:25 CET

  Making a Case for Active Surveillance After Response in N1/2 Disease
  
• 14:25 - 14:30 CET

  Making a Case for Surgery After Response in N1/2 Disease
• 14:30 - 14:35 CET

  Making a Case for Bladder Preservation After Response in N1/2 Disease
  

  Speaker: Vedang Murthy
• 14:35 - 14:39 CET

  N3 and M1a Disease After Response to Systemic Therapy (Introduction)
  

  Speaker: Neema Navai – UT MD Anderson Cancer Center
• 14:39 - 14:47 CET

  Local consolidative approaches in N3 and oligometastatic M1a disease
  

  Speaker: Leslie Ballas – Cedars-Sinai Medical Center
• 14:47 - 14:55 CET

  Would RC Ever Be an Option and Why?
  

  Speaker: Wassim Kassouf – McGill University Health Center
• 14:55 - 15:03 CET

  Precision and Risk-adapted Management in Metastatic UC - Treatment Breaks, Surveillance and Intensification Strategies Using ctDNA/MRD After Major Response
  
• 15:03 - 15:30 CET

  Case-based Panel - N2 MIBC, Not Responding to Therapy
  

  Moderator: Neema Navai – UT MD Anderson Cancer Center